systemic sclerosis
Conditions
Interventions
Non-tofacitinib group:Without tofacitinib
Sponsors
The Second Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: All the patients fulfilled the 2013 American College of Rheumatology and European Union League Against Rheumatism classification criteria of SSc. These patients enrolled in the study were aged between 18 and 80 years and had active disease (Rodnan Skin Score (mRSS) units = 10). SSc-ILD patients were defined as those with evidence of fibrosis on High-resolution CT (HRCT) findings, and a predicted forced vital capacity (FVC) of at least 50%
Exclusion criteria
Exclusion criteria: The patients were excluded from this study if they were allergic or intolerant to tofacitinib, suffering malignant disease, had a history of malignancy, a recent clinically significant infection, or had any other connective tissue disease, pulmonary interstitial lesions due to other causes, such as idiopathic and pharmaceutical, or coal dust and asbestos asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rodnan Skin Score (mRSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| the patients with an AE leading to withdrawal or a serious AE (SAE);a decrease in doses of prednisone or disease-modifying antirheumatic drugs (DMARDs) required to control disease activity; | — |
Countries
China
Contacts
Public ContactHong-yan Wen
The Second Hospital of Shanxi Medical University
Outcome results
None listed